These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 32628819)

  • 41. Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis.
    Machherndl-Spandl S; Sega W; Bösmüller H; Germing U; Gruber Ch; Nachtkamp K; Reinecke P; Sperr WR; Wimazal F; Müllauer L; Sotlar K; Horny HP; Tüchler H; Valent P; Krieger O
    Ann Hematol; 2014 Jan; 93(1):57-64. PubMed ID: 24241126
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multiple myeloma with bone marrow biopsy features simulating concomitant chronic idiopathic myelofibrosis.
    Schmidt U; Ruwe M; Leder LD
    Nouv Rev Fr Hematol (1978); 1995; 37(2):159-63. PubMed ID: 7644355
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The association between COX-2 expression and survival in myeloma patients.
    Vural F; Soyer N; Hekimgil M; Cagirgan S; Donmez A; Tombuloglu M
    Eur Rev Med Pharmacol Sci; 2014; 18(15):2132-6. PubMed ID: 25070817
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy.
    Kumar S; Gertz MA; Dispenzieri A; Lacy MQ; Wellik LA; Fonseca R; Lust JA; Witzig TE; Kyle RA; Greipp PR; Rajkumar SV
    Bone Marrow Transplant; 2004 Aug; 34(3):235-9. PubMed ID: 15170170
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high-risk multiple myeloma in Asian patients.
    Byun JM; Shin DY; Hong J; Kim I; Kim HK; Lee DS; Koh Y; Yoon SS
    Cancer Med; 2018 Mar; 7(3):831-841. PubMed ID: 29380550
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study.
    Huang SY; Lin HH; Yao M; Tang JL; Wu SJ; Hou HA; Chou WC; Chou SC; Hsu SC; Ko BS; Lu HY; Tsay W; Tien HF
    PLoS One; 2015; 10(9):e0137552. PubMed ID: 26379028
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations.
    Bousquet M; Le Guellec S; Quelen C; Rigal-Huguet F; Delsol G; Brousset P
    Hum Pathol; 2006 Nov; 37(11):1458-64. PubMed ID: 16949922
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessment of bone marrow fibrosis and angiogenesis in monitoring patients with multiple myeloma.
    Babarović E; Valković T; Štifter S; Budisavljević I; Seili-Bekafigo I; Duletić-Načinović A; Lučin K; Jonjić N
    Am J Clin Pathol; 2012 Jun; 137(6):870-8. PubMed ID: 22586045
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression.
    Jung SH; Choi HJ; Shin MG; Lee SS; Hwang EC; Jung TY; Cho MS; Yang DH; Ahn JS; Kim YK; Kim HJ; Lee JJ
    Ann Hematol; 2016 Oct; 95(10):1645-51. PubMed ID: 27365142
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma.
    Chakraborty R; Muchtar E; Kumar SK; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
    Leuk Lymphoma; 2017 Feb; 58(2):308-315. PubMed ID: 27390076
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multiple myeloma.
    Röllig C; Knop S; Bornhäuser M
    Lancet; 2015 May; 385(9983):2197-208. PubMed ID: 25540889
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Real-world treatment patterns, resource use and cost burden of multiple myeloma in Portugal.
    Antunes L; Rocha-Gonçalves F; Chacim S; Lefèvre C; Pereira M; Pereira S; Zagorska A; Bento MJ
    Eur J Cancer Care (Engl); 2019 Jul; 28(4):e13026. PubMed ID: 30828907
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of bone marrow plasma cells percentage on survival at diagnosis and pre-transplant period in newly diagnosed multiple myeloma: Experience of a single center from Turkey.
    Ciftciler R; Goker H; Buyukasık Y; Aladag E; Saglam EA; Demiroglu H
    Transfus Apher Sci; 2019 Jun; 58(3):313-317. PubMed ID: 30928228
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adverse prognostic impact of bone marrow microvessel density in multiple myeloma.
    Lee N; Lee H; Moon SY; Sohn JY; Hwang SM; Yoon OJ; Youn HS; Eom HS; Kong SY
    Ann Lab Med; 2015 Nov; 35(6):563-9. PubMed ID: 26354343
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
    Usmani SZ; Nahi H; Plesner T; Weiss BM; Bahlis NJ; Belch A; Voorhees PM; Laubach JP; van de Donk NWCJ; Ahmadi T; Uhlar CM; Wang J; Feng H; Qi M; Richardson PG; Lonial S
    Lancet Haematol; 2020 Jun; 7(6):e447-e455. PubMed ID: 32470437
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant.
    Gaballa S; Saliba RM; Srour S; Lu G; Brammer JE; Shah N; Bashir Q; Patel K; Bock F; Parmar S; Hosing C; Popat U; Delgado R; Rondon G; Shah JJ; Manasanch EE; Orlowski RZ; Champlin R; Qazilbash MH
    Am J Hematol; 2016 Oct; 91(10):E442-7. PubMed ID: 27420405
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic value of bone marrow microvessel density and angiogenic cytokines in patients with multiple myeloma undergoing autologous stem cell transplant.
    Sucak GT; Aki SZ; Yüzbaşioğlu B; Akyürek N; Yağci M; Bağriaçik U; Haznedar R
    Leuk Lymphoma; 2011 Jul; 52(7):1281-9. PubMed ID: 21599578
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic significance of bone marrow histology in multiple myeloma.
    Subramanian R; Basu D; Dutta TK
    Indian J Cancer; 2009; 46(1):40-5. PubMed ID: 19282565
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.
    Oostvogels R; Jak M; Raymakers R; Mous R; Minnema MC
    Br J Haematol; 2018 Oct; 183(1):60-67. PubMed ID: 30080247
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma.
    Gonsalves WI; Timm MM; Rajkumar SV; Morice WG; Dispenzieri A; Buadi FK; Lacy MQ; Dingli D; Leung N; Kapoor P; Kyle RA; Gertz MA; Kumar SK
    Leuk Res; 2016 May; 44():32-9. PubMed ID: 26994849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.